Metrics as of 10/17/2026, 09:23 AM (Berlin time), refresh in progress.
Bio-Techne Stock
Bio-Techne Corporation
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Kim Kelderman
- Employees
- 3,000
- Market cap
- $11.4 B
- IPO
- 09/02/1989
Bio-Techne Corporation operates in the healthcare/biotechnology sector, providing essential reagents and instruments for research, diagnostics, and bioprocessing worldwide. The company operates through two segments consisting of Protein Sciences, which provides biological reagents such as cytokines or antibodies, and…
AI-generated company profile based on the figures on this page, last updated on 01/10/2026. Not investment advice.
Bio-Techne stock: price history
1D
+0.1%
1W
+0.2%
1M
+0.3%
6M
+22.5%
YTD
+23.4%
1Y
+17.8%
2Y
+1.1%
5Y
-41.7%
10Y
+174.6%
Next earnings date
Next earnings date
04/11/2026 (in 18 days)
Volatility around earnings
~95% stronger price swings than usual
Bio-Techne stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Very robust business model with strong megatrend tailwind: wide moat, strong pricing power, predictable revenue.
2 more assignments (Enabler/Second row) Pro-only.
Bio-Techne Corporation is a specialized provider in the life sciences sector that develops and distributes biological reagents, instruments, and services for research, diagnostics, and bioprocessing. The business is divided into two segments: Protein Sciences, which primarily deals with biological reagents such as antibodies, cytokines, and proteomics analysis tools, as well as Diagnostics and Spatial Biology, which provides molecular diagnostic assays, genetic kits, and oncology products. With revenue from consumables accounting for nearly 88 percent, the company operates a business model characterized by a high proportion of recurring revenues. The customer base extends globally across clinical diagnostics, research, and cell therapy.
- Revenue model
- Transactional
- Recurring revenue
- High
- Pricing power
- Moderate
- Moat
- Wide
- Moat type
- Switching costs
- Capital intensity
- Medium
- Customer concentration
- Unknown
Ask the agents about Bio-Techne
Analyst assessment of Bio-Techne
PRICE TARGET LOW
US$50.00
CONSENSUS
US$65.78
MEDIAN
US$73.00
PRICE TARGET HIGH
US$73.00
0
STRONG BUY
12
BUY
14
HOLD
0
SELL
0
STRONG SELL
26
TOTAL · Hold
As of: 13/08/2026
Bio-Techne stock metrics
P/E
62.03
P/B
5.37
EV/EBITDA
33.21
RETURN ON EQUITY
2.6%
NET MARGIN
17.0%
DEBT/EQUITY
0.14
DIVIDEND YIELD
0.4%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
99.4%
FLOAT SHARES
155,952,051
AVG. DAILY VOLUME (30D)
2,983,138
Insider transactions (SEC)
HIGGINS JOHN L
HIGGINS JOHN L
BAUMGARTNER ROBERT V
BAUMGARTNER ROBERT V
Hippel James
Attention
1 mention today in US forums, 50% fewer than yesterdayPrice since yesterday: +0.1%
Search (Google Trends)
Forums (Reddit)
Institutional holders
Dividends & Stock splits
Dividends
Stock splits
Smart Money
Register for free
Register now to see which funds are invested
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Comparable stocks
Frequently asked questions about Bio-Techne stock
What does Bio-Techne do?
Bio-Techne Corporation is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Kim Kelderman, the company employs around 3,000 people.
The IPO was on 09/02/1989; the stock trades on NASDAQ under the ticker TECH.
What do analysts say about Bio-Techne stock?
26 analysts rate the stock, the consensus is Hold (as of 13/08/2026).
The average price target is US$65.78, ranging from US$50.00 to US$73.00, with a median of US$73.00.
This is an external assessment, not a statement by Market Jury.
When does Bio-Techne report next?
The next earnings date is 04/11/2026.
Around past earnings, price swings were roughly 95% stronger than usual.
Does Bio-Techne pay a dividend?
Yes. The last dividend was US$0.08 per share, ex-date 24/08/2026, paid on 04/09/2026.
The dividend yield is 0.4% (as of 30/06/2026).
Which stocks are comparable to Bio-Techne?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Bio-Techne stock analyzed?
Clicking "Analyze stock" lets five strategies assess Bio-Techne against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.